Understanding the Barriers to Prostate Cancer Population-Based
Early Detection Programs: The PRAISE-U BEST Survey

J 2024

Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey

BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS et. al.

Basic information

Original name

Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey

Authors

BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS, Vera VASILYEVA, Juan Gomez RIVAS, Erik BRIERS, Thomas FRESE, Josep VILASECA, Shlomo VINKER, Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, Hendrik van POPPEL and Monique J ROOBOL

Edition

Journal of Personalized Medicine, Basel, MDPI, 2024, 2075-4426

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.508 in 2021

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/jpm14070751

UT WoS

001276999500001

Keywords in English

barriers; early detection; population-based screening; prostate cancer

Abstract

V originále

In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. Methods: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach. Results: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers). Conclusions: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.

Citovat

BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS, Vera VASILYEVA, Juan Gomez RIVAS, Erik BRIERS, Thomas FRESE, Josep VILASECA, Shlomo VINKER, Renata CHLOUPKOVÁ, Ondřej MÁJEK, Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, Hendrik van POPPEL and Monique J ROOBOL. Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey. Journal of Personalized Medicine. Basel: MDPI, 2024, vol. 14, No 7, p. 1-12. ISSN 2075-4426. Available from: https://dx.doi.org/10.3390/jpm14070751.

@article{2423152,
   author = {Beyer, Katharina and Leenen, Renee C A and Venderbos, Lionne D F and Helleman, Jozien and Remmers, Sebastiaan and Vasilyeva, Vera and Rivas, Juan Gomez and Briers, Erik and Frese, Thomas and Vilaseca, Josep and Vinker, Shlomo and Chloupková, Renata and Májek, Ondřej and Annemans, Lieven and Vynckier, Pieter and Basu, Partha and Chandran, Arunah and Roderick, van den Bergh and Collen, Sarah and Poppel, Hendrik van and Roobol, Monique J},
   article_location = {Basel},
   article_number = {7},
   doi = {http://dx.doi.org/10.3390/jpm14070751},
   keywords = {barriers; early detection; population-based screening; prostate cancer},
   language = {eng},
   issn = {2075-4426},
   journal = {Journal of Personalized Medicine},
   title = {Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey},
   url = {https://www.mdpi.com/2075-4426/14/7/751},
   volume = {14},
   year = {2024}
}

TY  - JOUR
ID  - 2423152
AU  - Beyer, Katharina - Leenen, Renee C A - Venderbos, Lionne D F - Helleman, Jozien - Remmers, Sebastiaan - Vasilyeva, Vera - Rivas, Juan Gomez - Briers, Erik - Frese, Thomas - Vilaseca, Josep - Vinker, Shlomo - Chloupková, Renata - Májek, Ondřej - Annemans, Lieven - Vynckier, Pieter - Basu, Partha - Chandran, Arunah - Roderick, van den Bergh - Collen, Sarah - Poppel, Hendrik van - Roobol, Monique J
PY  - 2024
TI  - Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey
JF  - Journal of Personalized Medicine
VL  - 14
IS  - 7
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20754426
KW  - barriers
KW  - early detection
KW  - population-based screening
KW  - prostate cancer
UR  - https://www.mdpi.com/2075-4426/14/7/751
N2  - In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with this recommendation, the PRAISE-U (Prostate Cancer Awareness and Initiative for Screening in the European Union (EU)) project was initiated. As part of the PRAISE-U, we aim to understand the current practice towards early detection in the EU MSs, the barriers to implementing or planning population-based screening programmes, and potential solutions to overcome these barriers. Methods: We adapted the Barriers to Effective Screening Tool (BEST) survey to the PCa context. However, it has not been validated in this context. We translated it into all spoken languages in the EU27 and disseminated it to different stakeholders across the EU using a snowballing approach. Results: We received 410 responses from 55 countries, of which 301 (73%) were from the 27 EU MSs. The most represented stakeholder group was urologists (218 (54%)), followed by general practitioners (GPs) (83 (21%)), patient representatives (35 (9%)), policy stakeholders (27 (7%)), researchers (23 (6%)), oncologists, pathologists, radiologists, nurses, and others (16 (4%)) and one industry representative. Among all respondents, 286 (69%) reported the absence of a population-based screening programme, mainly attributed to resource limitations and a lack of political and medical society support. Out of these 286 respondents, 196 (69%) indicated that opportunistic screening is being applied in their country, and 199 (70%) expressed their support for population-based screening programmes (which was highest amongst patient representatives and urologists and lowest amongst GPs and policy stakeholders). The highest scored barriers were lack of political support, insufficient operational resources, and inadequate participation. Suggested solutions to overcome these included awareness campaigns, consensus meetings, political lobbying and European guidelines (to overcome political support barriers), compatible IT systems (to overcome operational barriers), and easy access (to overcome participation barriers). Conclusions: Participants have noted the presence of opportunistic screening, and particularly urologists and patient representatives expressed their support for the establishment of a population-based PCa screening programme. Nevertheless, successful implementation of population-based screening programmes is complex; it requires political and medical society support, operational resources and capacity, awareness campaigns, as well as the development of protocols, guidelines, and legal frameworks.
ER  -

BEYER, Katharina, Renee C A LEENEN, Lionne D F VENDERBOS, Jozien HELLEMAN, Sebastiaan REMMERS, Vera VASILYEVA, Juan Gomez RIVAS, Erik BRIERS, Thomas FRESE, Josep VILASECA, Shlomo VINKER, Renata CHLOUPKOVÁ, Ondřej MÁJEK, Lieven ANNEMANS, Pieter VYNCKIER, Partha BASU, Arunah CHANDRAN, van den Bergh RODERICK, Sarah COLLEN, Hendrik van POPPEL and Monique J ROOBOL. Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey. \textit{Journal of Personalized Medicine}. Basel: MDPI, 2024, vol.~14, No~7, p.~1-12. ISSN~2075-4426. Available from: https://dx.doi.org/10.3390/jpm14070751.

Detailed Information on Publication Record